ライフサイエンスコーパス: vancomycin-resistant Enterococcus

1 ction was masked by the prior isolation of a vancomycin-resistant enterococcus.

2 hicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus.

3 its parent compound, vancomycin (V), against vancomycin-resistant enterococcus.

4 gnificantly reduces fecal bacterial loads of Vancomycin-Resistant Enterococcus.

5 hicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus.

6 sistant Staphylococcus aureus infections and vancomycin-resistant enterococcus.

7 hicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus.

8 osa, 15 of 86 (17.4%; 95% CI 9.4% to 25.4%), vancomycin-resistant Enterococcus, 25 of 180 (13.9%, 95%

9 to appropriate antibiotic for patients with vancomycin-resistant Enterococcus (4.2 versus 43.7 h; P=

10 For vancomycin-resistant Enterococcus, a four-variable class

11 thicillin-resistant Staphylococcus aureus or vancomycin-resistant Enterococcus admission surveillance

12 hicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus and no increase in adv

13 methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and carbapenem-resist

14 cus pneumoniae, beta-hemolytic streptococci, vancomycin-resistant Enterococcus, and Enterobacteriacea

15 ltidrug resistant organisms, including MRSA, vancomycin-resistant enterococcus, and Gram-negative org

16 extended spectrum beta-lactamase producers, vancomycin-resistant enterococcus, and highly-resistant

17 hylococcus aureus, Clostridioides difficile, vancomycin-resistant Enterococcus, and MDR gram-negative

18 hicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococcus are inconsistent with

19 nterococcal domination increased the risk of Vancomycin-resistant Enterococcus bacteremia 9-fold, and

20 For patients with vancomycin-resistant Enterococcus bacteremia, the mean t

21 Vancomycin-resistant Enterococcus bloodstream infections

22 Vancomycin-resistant Enterococcus bloodstream infections

23 ancomycin on susceptibility to C. difficile, vancomycin-resistant Enterococcus, carbapenem-resistant

24 The secondary outcome was vancomycin-resistant Enterococcus carriage in stool.

25 Vancomycin-resistant Enterococcus carriage was found in

26 proof of concept, wild-type (ATCC 29212) and vancomycin-resistant Enterococcus cells were incubated a

27 The primary outcome was MRSA or vancomycin-resistant enterococcus clinical cultures attr

28 methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococcus, Clostridium difficile

29 There were no cases of vancomycin-resistant Enterococcus colonization in patien

30 e detected, including increased incidence of vancomycin-resistant Enterococcus colonization or diseas

31 hicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus colonization were intr

32 cility in the past year were associated with vancomycin-resistant Enterococcus colonization.

33 relatedness, including the first known U.S. vancomycin-resistant enterococcus (E. faecalis strain V5

34 ~8-fold and 2~4-fold greater potency against vancomycin resistant Enterococcus faecalis and methicill

35 ses consisted of 1 patient with recalcitrant vancomycin-resistant Enterococcus faecalis (VRE) and 2 p

36 against vancomycin-susceptible organisms and vancomycin-resistant Enterococcus faecalis (VRE) of VanB

37 n-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus faecalis (VRE), and an

38 eus (MSSA, MRSA, and TRSA, respectively) and vancomycin-resistant Enterococcus faecalis (VRE).

39 sistant Streptococcus pneumoniae (PRSP), and vancomycin-resistant Enterococcus faecalis (VRE).

40 oxantrone (MTX) in vitro and in vivo against vancomycin-resistant Enterococcus faecalis (VRE).

41 . aureus (MRSA), Streptococcus pyogenes, and vancomycin-resistant Enterococcus faecalis (VRE).

42 Vancomycin-resistant Enterococcus faecalis (VREfs) is an

43 Vancomycin-resistant Enterococcus faecalis (VREfs) is an

44 A chromogenic medium for identification of vancomycin-resistant Enterococcus faecalis and Enterococ

45 investigate the changes to PG composition in vancomycin-resistant Enterococcus faecalis following the

46 n of the cell envelope of a clinical pair of vancomycin-resistant Enterococcus faecalis isolates from

47 and January 1995, we identified a cluster of vancomycin-resistant Enterococcus faecalis isolates invo

48 We found that GML suppresses growth of vancomycin-resistant Enterococcus faecalis on plates wit

49 methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecalis, extended-spe

50 rains carry transposon Tn1546, acquired from vancomycin-resistant Enterococcus faecalis, which is kno

51 he display of haptens on the cell surface of vancomycin-resistant Enterococcus faecalis.

52 hicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus faecalis.

53 hicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus faecalis.

54 hicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus faecalis.

55 llin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus faecalis/faecium (VREf

56 Although outbreaks of linezolid- and vancomycin-resistant Enterococcus faecium (LR-VRE) in so

57 rst clinical isolate of linezolid-resistant, vancomycin-resistant Enterococcus faecium (LRVRE).

58 stant S. aureus (1.3 +/- 0.4 microg/mL), and vancomycin-resistant Enterococcus faecium (MIC(50) 2.9 +

59 tbreaks involving three important pathogens: vancomycin-resistant Enterococcus faecium (n=19), methic

60 sus group (1), Streptococcus pneumoniae (6), vancomycin-resistant Enterococcus faecium (VRE FCM) (16)

61 onization of the gastrointestinal tract with vancomycin-resistant Enterococcus faecium (VRE) has beco

62 A mouse model of vancomycin-resistant Enterococcus faecium (VRE) intestin

63 Vancomycin-resistant Enterococcus faecium (VRE) is a lea

64 Vancomycin-resistant Enterococcus faecium (VRE) is a maj

65 REA), and epidemiological data for typing 45 vancomycin-resistant Enterococcus faecium (VRE) isolates

66 Genomic DNA extracted from 45 vancomycin-resistant Enterococcus faecium (VRE) isolates

67 Thirty-two isolates of vancomycin-resistant Enterococcus faecium (VRE) recovere

68 and a clinical prediction rule to guide anti-vancomycin-resistant Enterococcus faecium (VRE) therapy.

69 can inhibit dense colonization of the gut by vancomycin-resistant Enterococcus faecium (VRE), a leadi

70 llin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus faecium (VRE), and bet

71 llin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus faecium (VRE), Escheri

72 n resistance can lead to marked expansion of vancomycin-resistant Enterococcus faecium (VRE), Klebsie

73 To investigate the dissemination of vancomycin-resistant Enterococcus faecium (VREF) in a 72

74 Vancomycin-resistant Enterococcus faecium (VREF) was iso

75 n-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus faecium (VREF) with MI

76 n-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus faecium (VREF).

77 inal colonization by the nosocomial pathogen vancomycin-resistant Enterococcus faecium (VREfm) can le

78 e is known about the population structure of vancomycin-resistant Enterococcus faecium (VREfm) in Lat

79 Vancomycin-resistant Enterococcus faecium (VREfm) is a l

80 Vancomycin-resistant Enterococcus faecium (VREfm) is a l

81 Vancomycin-resistant Enterococcus faecium (VREfm) is an

82 Nosocomial acquisition and transmission of vancomycin-resistant Enterococcus faecium (VREfm) is the

83 ith multidrug-resistant organisms, including vancomycin-resistant Enterococcus faecium (VREfm).

84 mia, 54 (19.6%) were due to rESKAPE strains (vancomycin-resistant Enterococcus faecium [0], methicill

85 Many of these resistant microbes, such as vancomycin-resistant Enterococcus faecium and carbapenem

86 medium designed to recover and differentiate vancomycin-resistant Enterococcus faecium and Enterococc

87 Gram-positive bacteria (high priority) were vancomycin-resistant Enterococcus faecium and meticillin

88 rointestinal colonization by ampicillin- and vancomycin-resistant Enterococcus faecium C68 in a mouse

89 lishment of gastrointestinal colonization by vancomycin-resistant Enterococcus faecium C68 in a mouse

90 OG1RF and against two serologically related, vancomycin-resistant Enterococcus faecium clinical isola

91 The patient remained febrile and grew vancomycin-resistant Enterococcus faecium from the cereb

92 wth of antibiotic-resistant bacteria such as vancomycin-resistant Enterococcus faecium in vitro.

93 In particular, vancomycin-resistant Enterococcus faecium infections hav

94 ons; lower respiratory tract infections; and vancomycin-resistant Enterococcus faecium infections, in

95 ted States in late 1999 for the treatment of vancomycin-resistant Enterococcus faecium infections.

96 We also detect npmA2 in two vancomycin-resistant Enterococcus faecium isolates from

97 an also identify isolated colonies as either vancomycin-resistant Enterococcus faecium or Enterococcu

98 dition, this serum killed two (28%) of seven vancomycin-resistant Enterococcus faecium strains.

99 methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and beta-lact

100 fied that both inhibited and dispersed MRSA, vancomycin-resistant Enterococcus faecium, and Staphyloc

101 e may find future use as antibiotics against vancomycin-resistant Enterococcus faecium, methicillin-r

102 istant to ampicillin and vancomycin, such as vancomycin-resistant Enterococcus faecium.

103 pneumoniae and Acinetobacter baumannii, and vancomycin-resistant Enterococcus faecium.

104 hicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus faecium.

105 S), we identified one neonate colonized with vancomycin-resistant Enterococcus faecium.

106 hicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus faecium.

107 It displays narrow-spectrum activity against vancomycin-resistant Enterococcus faecium.

108 reus, vancomycin-intermediate S. aureus, and vancomycin-resistant Enterococcus faecium.

109 iridae and Siphoviridae families that target Vancomycin-Resistant Enterococcus gut colonization.

110 ately controlled and powered, infection with vancomycin-resistant enterococcus has had more of an eff

111 hicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus in a neurocritical car

112 k we analyzed data observed on the spread of vancomycin-resistant Enterococcus in an intensive care u

113 hicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus in neurocritical care

114 46 has only been described in human clinical vancomycin-resistant enterococcus isolates unique to the

115 ifficile infection and dense colonization by vancomycin-resistant Enterococcus, K. pneumoniae, and E.

116 pears to be a safe and effective therapy for vancomycin-resistant enterococcus meningitis.

117 im-sulfamethoxazole-resistant MRSA (n = 10), vancomycin-resistant Enterococcus (n = 37), high-level g

118 s aureus: RRRR, 0.87; 95% CI, 0.75-1.00; and vancomycin-resistant Enterococcus: RRRR, 0.82; 95% CI, 0

119 ria monocytogenes, Bacillus anthracis, and a vancomycin-resistant Enterococcus sp. with MIC or IC50 v

120 d for detection of Staphylococcus aureus and vancomycin-resistant Enterococcus species (VRE) using a

121 stant Enterobacterales species and 60.4% for vancomycin-resistant Enterococcus species.

122 istance to colonization by clinically vexing vancomycin-resistant Enterococcus species.

123 ation of methicillin resistant S. aureus and vancomycin resistant Enterococcus spp. was completed an

124 llin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus spp. (VRE), extended-s

125 methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus spp. and several multi

126 y detecting and discriminating genotypes for vancomycin-resistant Enterococcus spp. in the clinical l

127 icillin-resistant Staphylococcus aureus, and vancomycin-resistant Enterococcus spp. in the environmen

128 ncept, amplification of a gene specific to a vancomycin-resistant Enterococcus strain was performed o

129 hicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus surveillance cultures.

130 Indeed, a delayed vancomycin-resistant Enterococcus transmission component

131 n-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE) among ICU patien

132 Data on MRSA, C. difficile, vancomycin-resistant Enterococcus (VRE) and ICU-acquired

133 cus aureus (MRSA), Clostridium difficile, or vancomycin-resistant Enterococcus (VRE) and severity and

134 Vancomycin-resistant Enterococcus (VRE) are highly antib

135 We examined the impact of vancomycin-resistant Enterococcus (VRE) bloodstream infe

136 by the highly antibiotic-resistant bacterium vancomycin-resistant Enterococcus (VRE) can exceed 10(9)

137 lin azide agar plus vancomycin to screen for vancomycin-resistant enterococcus (VRE) colonization.

138 Vancomycin-resistant Enterococcus (VRE) has become a sig

139 n-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococcus (VRE) have achieved si

140 -resistant Staphylococcus aureus (MRSA), and vancomycin-resistant Enterococcus (VRE) in patients with

141 Nosocomial vancomycin-resistant Enterococcus (VRE) infections have

142 Treatment of vancomycin-resistant Enterococcus (VRE) infections is li

143 Bloodstream infection (BSI) to due vancomycin-resistant Enterococcus (VRE) is an important

144 Gut pathogen colonization with vancomycin-resistant Enterococcus (VRE) is common in the

145 n-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE) is driving the d

146 Infections attributable to vancomycin-resistant Enterococcus (VRE) strains have bec

147 ecovered from perirectal swabs collected for vancomycin-resistant Enterococcus (VRE) surveillance as

148 Data on MRSA, C. difficile, vancomycin-resistant Enterococcus (VRE), and ICU-acquire

149 llin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE), and MDR Enterob

150 erior to direct plating for the detection of vancomycin-resistant enterococcus (VRE), but vancomycin

151 llin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococcus (VRE), extended-spectr

152 with antibiotic-resistant bacteria, such as vancomycin-resistant Enterococcus (VRE), is a dangerous

153 ighly antibiotic-resistant bacteria, such as vancomycin-resistant Enterococcus (VRE), is a growing cl

154 nce can result in intestinal domination with vancomycin-resistant Enterococcus (VRE), leading to bloo

155 parent drug, including the ESKAPE pathogens, vancomycin-resistant Enterococcus (VRE), methicillin-res

156 llin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE), Pseudomonas aer

157 n-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE), while also exhi

158 n-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococcus (VRE).

159 sistant S. aureus (MRSA), S. pneumoniae, and vancomycin-resistant Enterococcus (VRE).

160 spitals discontinued contact precautions for vancomycin-resistant Enterococcus (VRE).

161 n-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococcus (VRE).

162 al of 142 stool specimens were evaluated for vancomycin-resistant enterococcus (VRE).

163 An adolescent with vancomycin-resistant Enterococcus was given standard dos

164 thicillin-resistant Staphylococcus aureus or vancomycin-resistant Enterococcus) was constructed.